- In a trial, lung cancer patients treated with AstraZeneca plc's AZN immunotherapy Imfinzi (durvalumab) pre- and post-surgery lived significantly longer without the disease progressing or recurring than those treated with chemotherapy.
- The late-stage study compared patients with resectable, early-stage, non-small cell lung cancer treated with Imfinzi and chemotherapy before surgery and as monotherapy after surgery to patients treated with chemotherapy pre-surgery.
- Topline results from a planned interim analysis of the AEGEAN Phase 3 study showed that Imfinzi plus neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery demonstrated a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy alone.
- Related: AstraZeneca Drug Imfinzi Fails As Monotherapy In Metastatic Lung Cancer Setting.
- Results from the final pathologic complete response and major pathologic response analyses were consistent with previously announced results.
- The trial will continue to assess key secondary endpoints, including disease-free survival (DFS) and overall survival (OS).
- Imfinzi was well tolerated, and there were no new safety concerns before and after surgery, AstraZeneca said.
- Price Action: AZN shares are up 1.51% at $65.10 during the premarket session on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
